Company intelligence / Profile preview
Neukio Biotherapeutics
Shanghai, Shanghai, Chinaneukio.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Neukio Biotherapeutics develops next-generation allogeneic cell therapies using induced pluripotent stem cell (iPSC)-derived natural killer (NK) and T cells engineered with chimeric antigen receptors (CARs). Their lead programs target solid tumors using scalable, off-the-shelf products enabled by proprietary gene-editing and manufacturing technologies. The company has rapidly advanced from founding in mid–2021 to having its first two candidates enter clinical trials by late–2024. No published human efficacy data yet; preclinical results support further development.
- Therapeutic areas
- OncologyImmunology
- Modalities
- Allogeneic cell therapyiPSC-derived CAR-NK cellsiPSC-derived CAR-T cellsGene-edited immune cell therapies
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
EdiGene (gene-editing technology collaboration)Tofflon Life Sciences (bioreactor technology partnership)
Beyond the preview
Go deeper on Neukio Biotherapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Neukio Biotherapeutics.